Full-Life Technologies’ 225Ac-FL-020 Gains the US FDA’s Fast Track Designation to Treat Metastatic Castration-Resistant Prostate Cancer
Shots:
- The US FDA has granted fast track designation to 225Ac-FL-020 for treating metastatic castration-resistant prostate cancer (mCRPC). Its IND for P-I was approved in May 2024 by the US FDA
- The P-I trial is intended to investigate the safety, tolerability and anti-tumor activity of 225Ac-FL-020 (a next-gen. UniRDC platform-based PSMA-targeting radionuclide drug conjugate) for the treatment of mCRPC
- 225Ac-FL-020 showed anti-tumor activity and a favorable safety profile in LNCaP xenograft mice. However, radiolabeled FL-020 exhibited a favorable in vivo biodistribution profile, consistent tumor uptake & a fast systemic clearance in non-clinical studies
Ref: Full-Life Technologies | Image: Full-Life Technologies
Related News:- Tubulis Reports the US FDA’s Fast Track Designation of TUB-040 to Treat Ovarian Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
